Silodosin is an urologic drug developed by the U.S. Food And Drug Administration and initially approved in Oct 2008, for treating the symptoms of benign prostatic hyperplasia.

Silodosin helps to treat the signs and symptoms of benign prostatic hyperplasia (BPH) with an enlarged prostate in adult men.

Silodosin is a prescription medicine available as a tablet in two doses, Silodosin 4mg and Silodosin 8mg. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

The side effects known to occur commonly during the treatment with Silodosin are dizziness, runny or blocked nose, diarrhea, impotence and low sex drive, low sperm count and movement, enlarged or painful breasts. Some serious side effects also include severe allergic reactions (swelling on the face, tongue, or throat), skin reactions and irregular heartbeat.

The prostate gland enlarges its size after 40 years of age. BPH symptoms include frequent urination, urgency, restriction of the urine flow, and painful bladder. Acute urine retention, characterized by painful urination, is most likely to develop in people with benign prostatic hyperplasia.

Inform your doctor before using Silodosin if you have severe liver or kidney problems, dizziness, having cataract surgery, or have been taking blood pressure or antifungal medications.0

Tell your doctor before the treatment commencement if you have lung and kidney disease. If you have ever fainted or felt dizzy when suddenly standing up, consult your doctor before taking this medication, as it reduces blood pressure. Avoid making plans to have children because this medicine leads to abnormal ejaculation (decreases the amount of semen released during sex) that temporarily affects male fertility.

1. Recordati Ireland Ltd., European Medicines Agency (EMA), [Revised on Sep 2014] [Accessed on 3 June 2023], https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf
2. Watson Laboratories, Inc., US Food & Drug Administration, [Revised on Jan 2013] [Accessed on 3 June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf
3. Rossi M, Roumeguere T; Silodosin in treating benign prostatic hyperplasia. Published on 27th October 2010;[Accessed on 3 June 2023];  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990389/
4. Edward Chu, Lange’s Basic and clinical pharmacology, Adrenoceptors antagonist drugs,14th Edition, 2018, 160-161.

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.